Siglec-7 restores β-cell function and survival and reduces inflammation in pancreatic islets from patients with diabetes
Citations Over TimeTop 10% of 2017 papers
Abstract
Chronic inflammation plays a key role in both type 1 and type 2 diabetes. Cytokine and chemokine production within the islets in a diabetic milieu results in β-cell failure and diabetes progression. Identification of targets, which both prevent macrophage activation and infiltration into islets and restore β-cell functionality is essential for effective diabetes therapy. We report that certain Sialic-acid-binding immunoglobulin-like-lectins (siglecs) are expressed in human pancreatic islets in a cell-type specific manner. Siglec-7 was expressed on β-cells and down-regulated in type 1 and type 2 diabetes and in infiltrating activated immune cells. Over-expression of Siglec-7 in diabetic islets reduced cytokines, prevented β-cell dysfunction and apoptosis and reduced recruiting of migrating monocytes. Our data suggest that restoration of human Siglec-7 expression may be a novel therapeutic strategy targeted to both inhibition of immune activation and preservation of β-cell function and survival.
Related Papers
- → Molecular cloning of porcine Siglec-3, Siglec-5 and Siglec-10, and identification of Siglec-10 as an alternative receptor for porcine reproductive and respiratory syndrome virus (PRRSV)(2017)33 cited
- → Coevolution of Siglec-11 and Siglec-16 via gene conversion in primates(2017)31 cited
- → Regulation of mast cells by overlapping but distinct protein interactions of Siglec‐6 and Siglec‐8(2024)8 cited
- → Discovering a sialic acid independent ligand for paired receptors Siglec‐5 and ‐14 (1003.5)(2014)
- → Faculty Opinions recommendation of Defining the in vivo function of Siglec-F, a CD33-related Siglec expressed on mouse eosinophils.(2007)